Abiopharma

🔍 Meister Keith A. (Executive)

Company: ILLUMINA, INC. (ILMN)

Report Date: 2026-05-07

Detailed Transactions and Holdings:

• Acquired 9,236 shares of Common Stock at $102.82 per share (Direct)
  Date: 2026-05-07 | Code: X | equity_swap_involved: 1 | shares_owned_after: 3,838,744.00 | transaction_form_type: 4 | Footnotes: F3, F1
• Sold 9,236 shares of Common Stock at $140.25 per share (Direct)
  Date: 2026-05-07 | Code: J | equity_swap_involved: 1 | shares_owned_after: 3,829,508.00 | transaction_form_type: 4 | Footnotes: F3, F1
• Acquired 79,568 shares of Common Stock at $102.82 per share (Direct)
  Date: 2026-05-11 | Code: X | equity_swap_involved: 1 | shares_owned_after: 3,909,076.00 | transaction_form_type: 4 | Footnotes: F4, F1
• Sold 79,568 shares of Common Stock at $143.45 per share (Direct)
  Date: 2026-05-11 | Code: J | equity_swap_involved: 1 | shares_owned_after: 3,829,508.00 | transaction_form_type: 4 | Footnotes: F4, F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-05-07 | Code: H | shares_owned_after: 4,566.00
• Sold 9,236 shares of Equity Swap (right to buy) at $102.82 per share (Derivative)
  Date: 2026-05-07 | Code: X | Expires: 2028-02-11 | equity_swap_involved: 1 | shares_owned_after: 359,508.00 | transaction_form_type: 4 | Footnotes: F3, F3, F3, F1
• Sold 79,568 shares of Equity Swap (right to buy) at $102.82 per share (Derivative)
  Date: 2026-05-11 | Code: X | Expires: 2028-02-11 | equity_swap_involved: 1 | shares_owned_after: 279,940.00 | transaction_form_type: 4 | Footnotes: F4, F4, F3, F1

Footnotes:

• F1: These securities of Illumina, Inc. (the "Issuer") are held for the accounts of certain private investment funds (collectively, the "Corvex Funds") for which Corvex Management LP ("Corvex") acts as investment adviser, including Corvex Master Fund LP and Corvex Select Equity Master Fund LP. The general partner of Corvex is controlled by Keith Meister.
• F2: For the purposes of this filing, each of Corvex and Mr. Meister disclaims beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein. This filing shall not be deemed an admission that Corvex or Mr. Meister is the beneficial owner of any of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise.
• F3: As previously reported, the Corvex Funds had entered into equity swaps that represented an aggregate economic long-side exposure comparable to a notional interest in 368,744 shares of common stock of the Issuer. Under the terms of the swaps, the value to be received or paid upon termination of a swap will be determined by the difference in the market price per notional share of common stock on the date of termination as compared to the cost of such notional share of common stock at the time of entry into the swap. On May 7, 2026, upon partial termination of the swaps as reported in Table II above, the swaps counterparty paid to the Corvex Funds $1,295,349, representing $140.25 per share for each of the 9,236 notional shares subject to the termination (the market price of the common stock on the date of the partial termination), offset by $949,645.52, representing $102.82 for each of such 9,236 notional shares.
• F4: In addition, on May 11, 2026, upon partial termination of the swaps as reported in Table II above, the swaps counterparty paid to the Corvex Funds $11,414,029.60, representing $143.45 per share for each of the 79,568 notional shares subject to the termination (the market price of the common stock on the date of the partial termination), offset by $8,181,181.76, representing $102.82 for each of such 79,568 notional shares.
• F5: The partial termination of the equity swaps and the reported purchases of common stock in connection therewith are deemed exempt from Section 16(b) of the Securities Exchange Act of 1934 pursuant to Rule 16b-6(b) thereunder. The remaining swaps terminate on February 11, 2028, and have a cost basis of $102.82 per notional share of common stock. All balances will be settled in cash by default. At the option of the Corvex Funds, the remaining portion of the swaps may be physically settled by the Corvex Funds acquiring 279,940 shares of common stock from the counterparty at $102.82 per share.